Aviceda completes IND-enabling toxicity studies with lead ophthalmic drug candidate in nonhuman primates
Dec. 7, 2022
Aviceda Therapeutics LLC has completed IND-enabling good laboratory practice (GLP) toxicity studies of its lead ophthalmic drug candidate, AVD-104, in nonhuman primates and rabbits.
